Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pliant Therapeutics Inc PLRX

Healthcare
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avß6 and avß1 integrins that is in development in the lead indications for the treatment of idiopathic... see more

Recent & Breaking News (NDAQ:PLRX)

Pliant Therapeutics Announces Presentations at the International Liver Congress(TM) 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial

GlobeNewswire June 24, 2022

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

GlobeNewswire June 22, 2022

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

GlobeNewswire June 16, 2022

Pliant Therapeutics Announces Presentations at the International Liver Congress(TM) 2022

GlobeNewswire June 15, 2022

Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference

GlobeNewswire May 18, 2022

Pliant Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire May 11, 2022

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 9, 2022

Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809

GlobeNewswire May 5, 2022

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire May 3, 2022

Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference

GlobeNewswire May 2, 2022

Pliant Therapeutics to Participate in Needham Healthcare Conference

GlobeNewswire April 5, 2022

CORRECTION - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire February 28, 2022

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire February 28, 2022

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers

GlobeNewswire February 28, 2022

Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

GlobeNewswire February 24, 2022

Pliant Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 24, 2022

Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones

GlobeNewswire January 11, 2022

Pliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 21, 2021

Pliant Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 18, 2021

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

GlobeNewswire November 9, 2021